celluar and firm cream for post glp-1 med Future Veil® & Repair Peptide 1 medications ✨ On GLP-1s? Let's talk

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list, finding no clinical need for large-scale compounding of these medications from bulk substances

Interestingly, animal studies have shown that when beta-3 adrenergic receptors were genetically removed, chronic AOD-9604 treatment produced no changes in weight or lipolysis

Selenocysteine robustness versus cysteine versatility: a hypothesis on the evolution of the moonlighting behaviour of peroxiredoxins

"Not FDA-approved" does not mean unregulated

Although no significant change was observed in the bone formation marker P1NP, the semaglutide group showed a significant increase in the bone resorption marker CTX and a reduction in areal BMD at both the lumbar spine and total hip

The dual receptor advantage Semaglutide activates one receptor